Neuralstem (NASDAQ:CUR) Stock Rating Upgraded by ValuEngine

Neuralstem (NASDAQ:CUR) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Wednesday, ValuEngine reports.

CUR stock traded up $0.02 during midday trading on Wednesday, hitting $2.17. The stock had a trading volume of 500 shares, compared to its average volume of 183,608. Neuralstem has a 1-year low of $2.09 and a 1-year high of $27.40. The company’s fifty day moving average price is $1.46.

Neuralstem (NASDAQ:CUR) last released its earnings results on Tuesday, May 14th. The company reported ($3.40) earnings per share (EPS) for the quarter. Neuralstem had a negative net margin of 2,248.47% and a negative return on equity of 118.28%.

About Neuralstem

Neuralstem, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.

Featured Article: What does relative strength index mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.